Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PharmaFrontiers given FDA go ahead for MS trial
The company believes that completion of this trial will allow the launch of a pivotal phase III trial for the drug. This phase IIb clinical study is designed
The company believes that completion of this trial will allow the launch of a pivotal phase III trial for the drug. This phase IIb clinical study is designed
In a paper published in Nature the scientists describe the rational design of a potential new class of chemically modified RNA-based drugs, called ‘antagomirs’, that specifically silence miRNAs
The new project will expand clinical evaluation of the world’s most advanced malaria vaccine candidate, known as RTS,S. If all the project milestones are achieved, this agreement will
The approval is specifically for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to, or has
In September, an FDA advisory committee recommended approval of Exubera for the treatment of adults with type 1 and type 2 diabetes. The FDA is not obligated to
Based on careful review of the data and the observed benefit-risk profile, the trial’s independent Safety and Efficacy Monitoring Committee (SEMC) recommended that the study not resume enrollment.
Clobex spray was demonstrated to be safe and effective in two multi center, randomized, double-blind studies involving 209 patients with moderate-to-severe psoriasis. In the first clinical trial, 82%
As of November 2005, Theramed will use its sales force to promote and sell both products to targeted general practitioners and specialists throughout Canada, although it is expected
The merger agreement will see Novartis pay approximately $600 million more than its original bid. Chiron’s board had rejected the initial offer at the beginning of September having
Nearly 75% of study participants experienced improvement in ADHD symptoms, according to preliminary results of the study dubbed the Quality of Life, Effectiveness, Safety, and Tolerability trial (QUEST).